Enbiome’s current focus is on 3 disease segments.
NEUROBIOTIXTM Mitochondrial dsyfuction is a nodal point of many neurodegenerative disorders. Parkinson’s, Amyotrophic Lateral Sclerosis (ALS), Huntington’s, Multiple Sclerosis, ADHD and other neurological disorders have one convergent causative factor- mitochondrial dysfunction. Enbiome has identified 6 candidates which can repair mitochondrial dysfunction and promote its biogenesis. We have further tested our selected lead microbes against the various neurological disease models in multiple orthogonal models for each disease.
SKINBIOTIXTM: Eczema, Psoriasis and Atopic Dermatitis are allergic skin conditions, which are considered to stem from hyperactivation of our immune system. Skin microbiome of people suffering from allergic skin conditions is dramatically different from healthy individuals. Enbiome believes that the skin microbiome produces compounds that keep our skin immune response under check. We have identified a normal human skin microbe that could correct the improper activation of immune system. We have demonstrated suppression of hyperimmunity as well as ability of the bacterial metabolite to sequester inflammatory peptides.
GUTBIOTIXTM: Inflammatory bowel diseases (including Crohn's disease and Ulcerative colitis) and Irritable bowel syndrome are a group of disorders that affect the human gastrointestinal system. Interactions between microbiome and the intestinal cells are important in these chronic conditions. EnBiome's lead candidate produces compounds that upregulate tight junction proteins, thus keeping our intestinal epithelial cells happy and healthy. We have identified a key ingredient from this human gut commensal microbe that is also anti-inflammatory. We are evaluating the strategy of whole bacteria or combination of key active ingredients as a potential therapeutic product.
Summary of primary disease interactions between the gut and brain
We have isolated and identified 5 different candidates EBT404, EBT405, EBT406, EBT407, EBT408 which have demonstrated repair of mitochondrial dysfunction and promotion of mitochondrial biogenesis.
We are continuously testing these lead microbes against various neurodegenerative disease models
Our lead candidate EBT101 shows clearance of IBD pathogen E. coli AIEC LF82 in C. elegans
Responsible for recovery of gut size, morphology and animal body weight in Citrobacter-induced colitis mouse model
Upregulates tight junction proteins in epithelial cells
EBT101 also demonstrates resistance to oxidative stress, commonly seen in inflamed gut
SkinBiotX candidates are microbiome-derived microbes or microbial-derivatives that have:
Molecular targets of key active ingredients identified.